scholarly journals Blind liver biopsy: a 17-year experience

2020 ◽  
Vol 40 (4) ◽  
pp. 322
Author(s):  
Nafiye Urganci ◽  
Tugce Kurtaraner ◽  
Derya Kalyoncu ◽  
Ayse Merve Usta ◽  
Banu Yilmaz Ozguven
Keyword(s):  
Liver Biopsy ◽  
Chronic Active Hepatitis ◽  
Wilson Disease ◽  
Gold Standard ◽  
Liver Diseases ◽  
Liver Enzymes ◽  
Liver Inflammation ◽  
Safe Method ◽  
Biopsy Site ◽  
Histopathological Results

Objectives: Liver biopsy is the gold standard for assessing liver inflammation, necrosis and fibrosis. The aim of the study is to evaluate clinical indications and histopathological results of percutaneus liver biopsy. Materials and methods: A total of 516 children who underwent blind liver biopsy were evaluated retrospectively. Results: Blind liver biopsy was performed for chronic active hepatitis B in 50% of the cases (n=260), neonatal cholestasis in 14% (n=68), autoimmune hepatitis in 7.7% (n=40), Wilson disease in 7.3% (n=38), isolated elevation of the liver enzymes in 5% (n=26), chronic active hepatitis C in 4.2% (n=22), metabolic disease in 3.4% (n=17), malignancies in 2.2% (n=11) and the others in 3.4% (n=17). Major complications were observed in 0.19% of the cases (n=1) and minor complications such as pain at the biopsy site in 13.5% of the cases (n=70), hypotension and tachycardia in 1.9% (n=10). Conclusions: Blind liver biopsy is a safe method in diagnosing liver diseases in childhood.

scholarly journals Intrahepatic Hematoma and Haemobilia After Percutaneous Liver Biopsy: A Clinical Case Report

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Goran Sarafiloski ◽  
Mimi R. Marinova ◽  
Pencho T. Tonchev
Keyword(s):  
Liver Biopsy ◽  
Gold Standard ◽  
Liver Diseases ◽  
Bile Ducts ◽  
Clinical Manifestations ◽  
Massive Bleeding ◽  
Response To Treatment ◽  
Percutaneous Liver Biopsy ◽  
Chronic Anemia

Summary Assessing the severity of liver disease and predict the response to treatment in clinical practice requires the determination of the degree of inflammation progression and liver fibrosis. Percutaneous liver biopsy is the gold standard for grading and staging liver diseases. Complications are more common in the presence of vascular liver lesions, dilation of the bile ducts, ascites, or whether examination has been performed by less experienced physicians. Bleeding after liver biopsy is considered the most common cause of severe complications. Bleeding usually presents as a subcapsular or parenchymal hematoma, free intraperitoneal hemorrhage, hemobilia, or, rarely, hemothorax. The rarest of hemorrhagic complications is hemobilia, a term used to describe bleeding in the bile ducts. Hemobilia is usually suspected when there is a drop in hemoglobin after the procedure, pain in the upper right quadrant of the abdomen, hyperbilirubinemia, and unexplained gastrointestinal bleeding. The clinical manifestations range from chronic anemia to rapid, massive bleeding with hematemesis and/or melena.

scholarly journals Options of non-invasive assessment of liver fibrosis based on the clinical data

2015 ◽  
Vol 156 (2) ◽  
pp. 43-52 ◽  
Author(s):  
Anna Egresi ◽  
Gabriella Lengyel ◽  
Krisztina Hagymási
Keyword(s):  
Liver Fibrosis ◽  
Liver Biopsy ◽  
Gold Standard ◽  
Liver Diseases ◽  
Causes Of Death ◽  
Therapeutic Response ◽  
Transient Elastography ◽  
Chronic Liver Diseases ◽  
Indirect Methods ◽  
Non Invasive

Liver cirrhosis is one of the leading causes of death worldwide. Liver biopsy is considered as the gold standard for the diagnosis of chronic liver diseases. Studies have focused on non-invasive markers for liver fibrosis because of the dangers and complications of liver biopsy. The authors review the non-invasive direct as well as indirect methods for liver fibrosis assessment and present the positive and negative predictive value, sensitivity and specificity of those. Clinical utilities of transient elastography (Fibrsocan) is also reviewed. Non-invasive methods are useful in the assessment of liver fibrosis, monitoring disease progression and therapeutic response. Their accuracy can be increased by the combined or sequential use of non-invasive markers. Orv. Hetil., 2015, 156(2), 43–52.

scholarly journals Diagnostic Performance of Noninvasive Methods for Liver Biopsy by Fibroscan in Pediatric

2021 ◽  
Vol 11 (01) ◽  
pp. e55-e59
Author(s):  
Farzaneh Motamed ◽  
Ghobad Heidari ◽  
Bita Heirati ◽  
Parisa Rahmani
Keyword(s):  
Liver Biopsy ◽  
Liver Diseases ◽  
Storage Disease ◽  
Sampling Error ◽  
Medical Center ◽  
Glycogen Storage ◽  
Chronic Liver ◽  
Noninvasive Methods ◽  
Function Test ◽  
Diagnostic Modalities

AbstractLiver biopsy is the gold standard for the diagnosis and management of various liver diseases; however, noninvasive diagnostic modalities may help prevent adverse effects of anesthesia, prolonged hospitalization, sampling error, and other serious complications, particularly in pediatric patients. The aim of this study is to compare the results of liver biopsy and fibroscan in children with chronic liver diseases. All patients presenting chronic liver disease admitted in the ward or clinic of Tehran's Children Medical Center were enrolled in the study. Required laboratory tests were performed to diagnose the disease, followed by elastography using fibroscan 402 (M-probe) Echosens machine and liver biopsy using Menghini technique. Samples were scored by using METAVIR scoring system. Thirty-two patients were reported (68.8%, female) with autoimmune hepatitis (18.8%), Wilson disease (12.5%), and glycogen storage disease (12.5%). The most common pathologic stage and fibroscan result was stage III and F0 (46.9%), respectively. Association between pathology and fibroscan results was not significant. Nonetheless, age and diagnosis, age and Fibroscan score, and pathology and liver function test were significantly associated with each other. Fibroscan cannot be used as an alternative to liver biopsy; however, it can be a useful accessory tool.

scholarly journals Novel Laboratory Tests in Assessment of Liver Function in Acute and Chronic Liver Diseases

2009 ◽  
Vol 63 (4-5) ◽  
pp. 228-233
Author(s):  
Ludmila Vīksna ◽  
Jāzeps Keišs ◽  
Artūrs Sočņevs ◽  
Baiba Rozentāle ◽  
Māra Pilmane ◽  
...  
Keyword(s):  
Liver Function ◽  
Liver Biopsy ◽  
Liver Diseases ◽  
Laboratory Tests ◽  
Serum Markers ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Noninvasive Methods ◽  
Disease Evolution ◽  
Prognostic Accuracy

Novel Laboratory Tests in Assessment of Liver Function in Acute and Chronic Liver Diseases Liver biopsy in clinical practice has been widely used for the diagnosis and management of patients with liver diseases, particularly, with chronic liver diseases. However, liver biopsy is an invasive method with potential complications, sampling and interpretation errors. Therefore, noninvasive tests are being developed and introduced to replace liver biopsy. The aim of the present study was to identify the new noninvasive methods to be used for the assessment of liver structure and function, by use of the appropriate serum surrogate markers and to evaluate the clinical diagnostic and prognostic accuracy of these methods, including immunogenetic methods, in cases of acute and chronic liver diseases. The obtained data showed that serum markers of apoptosis (cytokeratin-18 neoepitope and citochrome c) and fibrosis (hyaluronic acid) should be included in viral and toxic liver damage management algorithms. The punctual identification of immunogenetic factors (HLA class II antigens) may prove to be useful in predicting disease evolution, and in guiding the appropriate therapy for patients with poor prognosis.

scholarly journals Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan

2011 ◽  
Vol 4 (1) ◽  
Author(s):  
Hidenori Toyoda ◽  
Takashi Kumada ◽  
Seiki Kiriyama ◽  
Makoto Tanikawa ◽  
Yasuhiro Hisanaga ◽  
...  
Keyword(s):  
Liver Biopsy ◽  
Fatty Liver ◽  
Viral Hepatitis ◽  
Liver Diseases ◽  
Alcoholic Fatty Liver

scholarly journals Liver involvement in patients with systemic lupus erythematosus

2021 ◽  
Vol 59 (2) ◽  
pp. 164-172
Author(s):  
A. P. Panova ◽  
V. G. Avdeev ◽  
T. N. Krasnova ◽  
T. P. Rozina ◽  
E. P. Pavlikova ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Differential Diagnosis ◽  
Lupus Erythematosus ◽  
Liver Diseases ◽  
Liver Enzymes ◽  
Liver Steatosis ◽  
Liver Involvement ◽  
Systemic Lupus ◽  
Viral Hepatitis C ◽  
Lupus Hepatitis

Liver involvement in systemic lupus erythematosus is common and in most cases clinical course is asymptomatic, that makes diagnosis difficult. Determination of the cause of the liver involvement is important to select treatment and to evaluate the prognosis of the disease.The aim of the research was to characterize the clinical features of liver involvement in patients with systemic lupus erythematosus and identify the most significant clinical and laboratory parameters for the differential diagnosis of lupus hepatitis.Materials and methods. The study included 313 patients with systemic lupus erythematosus observed in the E.M. Tareev Clinic of Rheumatology, Internal Medicine and Occupational Diseases of I.M. Sechenov First Moscow State Medical University (Sechenov University) in the period from 2001 to 2019. The verification of diagnosis of systemic lupus erythematosus was based on the criteria of the American College of Rheumatology (1997). Patients examination included complete blood count, biochemical and immunological blood tests and an abdominal ultrasonography. In 13 cases hepatic autoantibodies (ASMA, anti-LKM-1, LC-1, SLA-LP, AMA-M2) were analyzed, in 4 – magnetic resonance cholangiopancreatography and in 6 – liver biopsy were made.Results. Liver involvement were represented by an increase of liver enzymes in 58 (18.5%) cases. Chronic viral hepatitis C was diagnosed in 4 (1.3%) patients. Drug-induced hepatitis was found in 17 (5.4%) patients. Autoimmune liver diseases occured in 2 (0.6%) patients. In 2 (0.6%) patients, liver damage was associated with thrombotic microangiopathy (atypical hemolytic uremic syndrome, hereditary thrombophilia). In 15 (4.8%) cases, the most likely diagnosis was NAFLD. Lupus hepatitis was the most likely cause in 18 (5.7%) patients. Differential diagnosis in cases of liver involvement in patients with systemic lupus erythematosus requires assessment of risk factors for various liver diseases, age of the patients, level of liver enzymes, lupus activity, ultrasound signs of liver steatosis and secondary antiphospholipid syndrome.Determining the cause of the liver involvement for the patients with the systemic lupus erythematosus allows establishing better treatment tactic and improvement of the prognosis.

Sign in / Sign up

Export Citation Format

Share Document